Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPP: PAD-VCD and HSCT for Primary Plasma Cell Leukaemia
NCT02858999Phase 2Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Jan 2010
- Primary completion
- Jul 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib and lenalidomide in plasma cell leukaemia (PCL), sponsored by CHU Amiens-Picardie. Started Jan 2010; status: completed.
02
Drugs
bortezomiblenalidomide
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on NCT02858999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858999.